Metastatic prostate cancer is a heterogeneous disease entity. Men without prior androgen deprivation therapy exposure are termed metastatic castration sensitive prostate cancer (mCSPC). The goal of this article is to update the reader on the rapidly changing landscape of treatment for men with mCSPC. Along with the options available to the clinician for treatment of men with mCSPC, the care of these patients has evolved into a multi-disciplinary field with expanding roles for medical, urologic, and radiation oncologists.
Investigative and clinical urology. 2020 Jan 16 [Epub]
Daniel C Parker, Michael S Cookson
Department of Urology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK, USA.